Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
To determine which of the CDK4/6 inhibitors is the optimal treatment in metastatic luminal breast cancer. A network meta-analysis using the frequentist approach and generalized pairwise modeling was computed. The associations of aromatase inhibitor with ribociclib, palbociclib and abemaciclib were similar in efficacy. Palbociclib-based regimen was associated with significantly lower treatment discontinuation rates compared with the other approved drugs in this indication. In the absence of direct comparative evidence, the results of this network meta-analysis represent the best available evidence for decision making in the first-line treatment of metastatic luminal breast cancer.